Vemurafenib Side Effects

Some side effects of vemurafenib may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to vemurafenib: oral tablet

Along with its needed effects, vemurafenib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking vemurafenib:

More common
  • Blistering, peeling, or loosening of the skin
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • blurred vision or other change in vision
  • chills
  • cough
  • diarrhea
  • dizziness
  • eye pain
  • fainting
  • fast or irregular heartbeat
  • fever
  • increased sensitivity of the skin to sunlight
  • itching
  • joint or muscle pain
  • lump or growth on the skin
  • pain in the ankles or knees
  • painful, red lumps under the skin, mostly on the legs
  • paralysis of the nerves
  • rapid weight gain
  • rash with flat lesions or small raised lesions on the skin
  • red skin lesions, often with a purple center
  • red, irritated eyes
  • redness or other discoloration of the skin
  • redness, soreness, swelling, or itching skin
  • scaling of the skin on the hands and feet
  • sensitivity of the eye to light
  • severe sunburn
  • skin rash
  • sore throat
  • sores, ulcers, or white spots in the mouth or on the lips
  • sores, welting, or blisters
  • tearing
  • tingling of the hands and feet
  • ulceration of the skin
  • unusual tiredness or weakness
  • unusual weight gain or loss

Some side effects of vemurafenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Back or bone pain
  • burning, itching, and pain in the hairy areas, or pus at the root of the hair
  • change in taste
  • cough
  • decreased appetite
  • decreased weight
  • diarrhea
  • difficulty having a bowel movement (stool)
  • difficulty with moving
  • dry skin
  • hair loss or thinning of the hair
  • headache
  • lack or loss of strength
  • loss of taste
  • muscle stiffness
  • nausea
  • pain in the arms or legs
  • rash
  • sunburn
  • vomiting

For Healthcare Professionals

Applies to vemurafenib: oral tablet


Very common (10% or more): Skin papilloma (up to 30%), cutaneous SCC (24%), seborrheic keratosis (up to 14%)
Common (1% to 10%): Basal cell carcinoma, oropharyngeal squamous cell carcinoma
Postmarketing reports: Progression of a preexisting-existing chronic myelomonocytic leukemia with NRAS mutation


Uncommon (0.1% to 1%): Atrial fibrillation, vasculitis


Very common (10% or more): Hepatic laboratory abnormalities (GGT, AST, ALT, alkaline phosphatase, bilirubin) (up to 11.5%)


Common (1% to 10%): Cough


The most common side effects reported were arthralgia, rash, alopecia, fatigue, photosensitivity reaction, nausea, pruritus, and skin papilloma.


Very common (10% or more): Rash (up to 52%), photosensitivity (up to 49 %), alopecia (up to 45%), pruritus (up to 30%), hyperkeratosis (up to 28%), dry skin (up to 19%), erythema (up to 14%), sunburn (up to 14%)
Common (1% to 10%): Maculo-papular rash, actinic keratosis, papular rash, palmar-plantar erythrodysesthesia syndrome, keratosis pilaris, erythema nodosum, folliculitis
Uncommon (0.1% to 1%): Stevens-Johnson syndrome, toxic epidermal necrolysis
Postmarketing reports: DRESS syndrome


Very common (10% or more): Nausea (up to 37%), diarrhea (up to 29%), vomiting (up to 26%), constipation (up to 16%)


Very common (10% or more): Decreased appetite (up to 21%)


Very common (10% or more): Arthralgia (Up to 67%), myalgia (up to 24%), pain in extremity (up to 18%)
Common (1% to 10%): Musculoskeletal pain, back pain, arthritis
Uncommon (0.1% to 1%): VIIth nerve paralysis

Nervous system

Very common (10% or more): Headache (up to 27%), dysgeusia (up to 14%)
Common (1% to 10%): Dizziness, peripheral neuropathy


Very common (10% or more): Fatigue (up to 54%), peripheral edema (up to 23%), pyrexia (up to 19%), asthenia (up to 11%)


Common (1% to 10%): Uveitis
Uncommon (0.1% to 1%): Retinal vein occlusion

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.